MAR 0 5 2002

SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER

FOR PATENTS, WASHINGTON, DC 20231, ON THE DATE INDICATED BELOW:

DATE: January 14, 3

PATENT

ATTORNEY DOCKET NO.: 040853-01-5028-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	pplication of:)
Neose (forme	Technologies, Inc. rly, Neose Pharmaceuticals, Inc.))))
Application No.: 09/955,909))
Filing Date: September 18, 2001)
For:	METHOD FOR PRODUCING SIALYLOLIGOSACCHARIDES IN A DAIRY SOURCE)

Commissioner for Patents & Trademarks Washington, D.C. 20231

REVOCATION OF ORIGINAL POWER OF ATTORNEY AND GRANT OF NEW POWER OF ATTORNEY

Neose Technologies, Inc., formerly Neose Pharmaceuticals, Inc., a corporation located in Horsham, Pennsylvania, certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of assignment filed in application 08/911,393 and recorded on October 1, 1997 at Reel 8721, Frame 0070 in the U.S. Patent and Trademark Office.

Assignee hereby revokes the previous Power of Attorney in the above-identified patent application to <u>PENNIE & EDMONDS LLP</u> and hereby grants their power of attorney to the registered practitioners of <u>MORGAN, LEWIS & BOCKIUS LLP</u> included in the <u>Customer Number 028977</u> to transact all business, including prosecution, before the Patent and Trademark Office connected with this patent application. Assignee hereby respectfully requests that all correspondence be addressed directly to <u>MORGAN, LEWIS & BOCKIUS LLP</u> at the following location:

1701 Market Street Philadelphia, PA 19103

Please direct all telephone inquiries to:

Kathryn Doyle Phone: (215) 963-4723 To the best of the undersigned's knowledge and belief, title is in the assignee identified above. The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date:

Name: Stephen A. Roth

Title: Chief Executive Officer

Signature: